Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities
| dc.contributor.author | Versfeld, Anna | |
| dc.contributor.author | McBride, Angela | |
| dc.contributor.author | Scheibe, Andrew | |
| dc.contributor.author | Spearman, C W | |
| dc.date.accessioned | 2020-06-25T09:14:15Z | |
| dc.date.available | 2020-06-25T09:14:15Z | |
| dc.date.issued | 2020-06-10 | |
| dc.date.updated | 2020-06-14T03:16:27Z | |
| dc.description.abstract | Background Treatment of hepatitis C (HCV) among people who inject drugs (PWID) is a critical component of efforts to eliminate viral hepatitis. A recent study found high HCV prevalence among PWID in two cities, Pretoria (84%) and Cape Town (44%). Very few (< 5%) HCV-infected individuals attended follow-up appointments. This sub-study explores differences between stated desire for cure and appointment attendance in light of perceived facilitators and barriers to HCV treatment and care access among PWID. Method Two sets of semi-structured interviews were implemented in a group of HCV-infected participants opportunistically sampled and recruited at harm reduction service sites. Initial interviews, conducted before the planned hospital appointment date, asked participants (N = 17, 9 in Pretoria and 8 in Cape Town) about past experiences of healthcare provision, plans to attend their referral appointment and perceived barriers and facilitators to seeking hepatitis treatment. Second interviews (n = 9, 4 in Pretoria, 5 in Cape Town), conducted after the planned referral appointment date, asked about appointment attendance and treatment experience. Trained social scientists with experience with PWID conducted the interviews which were recorded in detailed written notes. Data was thematically analysed in NVivo 11. Results Despite routine experiences of being stigmatised by the healthcare system in the past, most participants (n = 16, 94%) indicated a desire to attend their appointments. Attendance motivators included the desire to be cured, fear of dying and the wish to assist the research project. Perceived barriers to appointment attendance included fear of again experiencing stigmatisation and concerns about waiting periods and drug withdrawal. Perceived facilitators included the knowledge they would be treated quickly, and with respect and access to opioid substitution therapy. In the end, very few participants (n = 5) went to their appointment. Actual barriers to attendance included lack of finances, lack of urgency and forgetting and fatalism about dying. Conclusions South Africa can learn from other countries implementing HCV treatment for PWID. Successful linkage to care will require accessible, sensitive services where waiting time is limited. Psychosocial support prior to initiating referrals that focuses on building and maintaining a sense of self-worth and emphasising that delayed treatment hampers health outcomes is needed. | en_US |
| dc.identifier.apacitation | Versfeld, A., McBride, A., Scheibe, A., & Spearman, C. W. (2020). Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. <i>Harm Reduction Journal</i>, 17(1), 39. | en_ZA |
| dc.identifier.chicagocitation | Versfeld, Anna, Angela McBride, Andrew Scheibe, and C W Spearman "Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities." <i>Harm Reduction Journal</i> 17, 1. (2020): 39. | en_ZA |
| dc.identifier.citation | Versfeld, A., McBride, A., Scheibe, A. & Spearman, C.W. 2020. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. <i>Harm Reduction Journal.</i> 17(1):39. | en_ZA |
| dc.identifier.ris | TY - Journal Article AU - Versfeld, Anna AU - McBride, Angela AU - Scheibe, Andrew AU - Spearman, C W AB - Background Treatment of hepatitis C (HCV) among people who inject drugs (PWID) is a critical component of efforts to eliminate viral hepatitis. A recent study found high HCV prevalence among PWID in two cities, Pretoria (84%) and Cape Town (44%). Very few (< 5%) HCV-infected individuals attended follow-up appointments. This sub-study explores differences between stated desire for cure and appointment attendance in light of perceived facilitators and barriers to HCV treatment and care access among PWID. Method Two sets of semi-structured interviews were implemented in a group of HCV-infected participants opportunistically sampled and recruited at harm reduction service sites. Initial interviews, conducted before the planned hospital appointment date, asked participants (N = 17, 9 in Pretoria and 8 in Cape Town) about past experiences of healthcare provision, plans to attend their referral appointment and perceived barriers and facilitators to seeking hepatitis treatment. Second interviews (n = 9, 4 in Pretoria, 5 in Cape Town), conducted after the planned referral appointment date, asked about appointment attendance and treatment experience. Trained social scientists with experience with PWID conducted the interviews which were recorded in detailed written notes. Data was thematically analysed in NVivo 11. Results Despite routine experiences of being stigmatised by the healthcare system in the past, most participants (n = 16, 94%) indicated a desire to attend their appointments. Attendance motivators included the desire to be cured, fear of dying and the wish to assist the research project. Perceived barriers to appointment attendance included fear of again experiencing stigmatisation and concerns about waiting periods and drug withdrawal. Perceived facilitators included the knowledge they would be treated quickly, and with respect and access to opioid substitution therapy. In the end, very few participants (n = 5) went to their appointment. Actual barriers to attendance included lack of finances, lack of urgency and forgetting and fatalism about dying. Conclusions South Africa can learn from other countries implementing HCV treatment for PWID. Successful linkage to care will require accessible, sensitive services where waiting time is limited. Psychosocial support prior to initiating referrals that focuses on building and maintaining a sense of self-worth and emphasising that delayed treatment hampers health outcomes is needed. DA - 2020-06-10 DB - OpenUCT DP - University of Cape Town IS - 1 J1 - Harm Reduction Journal KW - Hepatitis C treatment KW - HCV KW - People who inject drugs KW - Motivators KW - Facilitators KW - Barriers KW - South Africa LK - https://open.uct.ac.za PY - 2020 T1 - Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities TI - Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities UR - ER - | en_ZA |
| dc.identifier.uri | https://doi.org/10.1186/s12954-020-00382-3 | |
| dc.identifier.uri | https://hdl.handle.net/11427/32081 | |
| dc.identifier.vancouvercitation | Versfeld A, McBride A, Scheibe A, Spearman CW. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Harm Reduction Journal. 2020;17(1):39. . | en_ZA |
| dc.language.iso | en | en_US |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dc.source | Harm Reduction Journal | en_US |
| dc.source.journalissue | 1 | en_US |
| dc.source.journalvolume | 17 | en_US |
| dc.source.pagination | 39 | en_US |
| dc.source.uri | https://harmreductionjournal.biomedcentral.com/ | |
| dc.subject | Hepatitis C treatment | en_US |
| dc.subject | HCV | en_US |
| dc.subject | People who inject drugs | en_US |
| dc.subject | Motivators | en_US |
| dc.subject | Facilitators | en_US |
| dc.subject | Barriers | en_US |
| dc.subject | South Africa | en_US |
| dc.title | Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities | en_US |
| dc.type | Journal Article | en_US |